Olmesartan and Intestinal Adverse Effects in the ROADMAP Study
Authors:
- Jan MenneJMJan Menne
- Hermann HallerHHHermann Haller
- 1 December 2012
- journal article
- other
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 87 (12) , 1230-1231
Abstract
No abstract availableThis publication has 3 references indexed in Scilit:
- Severe Spruelike Enteropathy Associated With OlmesartanMayo Clinic Proceedings, 2012
- Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 DiabetesNew England Journal of Medicine, 2011
- Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) studyJournal Of Hypertension, 2006